A detailed history of Pacer Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Pacer Advisors, Inc. holds 10,917,626 shares of BMY stock, worth $631 Million. This represents 1.35% of its overall portfolio holdings.

Number of Shares
10,917,626
Previous 12,211,202 10.59%
Holding current value
$631 Million
Previous $507 Million 11.41%
% of portfolio
1.35%
Previous 1.3%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$39.66 - $51.75 $51.3 Million - $66.9 Million
-1,293,576 Reduced 10.59%
10,917,626 $565 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $123 Million - $162 Million
3,064,247 Added 33.5%
12,211,202 $507 Million
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $63.1 Million - $71.6 Million
1,316,007 Added 16.81%
9,146,955 $496 Million
Q4 2023

Jan 16, 2024

BUY
$48.48 - $57.85 $123 Million - $147 Million
2,540,360 Added 48.02%
7,830,948 $402 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $72.4 Million - $80.9 Million
1,249,846 Added 30.93%
5,290,588 $307 Million
Q2 2023

Jul 12, 2023

SELL
$63.71 - $70.74 $530,704 - $589,264
-8,330 Reduced 0.21%
4,040,742 $258 Million
Q1 2023

May 02, 2023

BUY
$65.71 - $74.53 $254 Million - $288 Million
3,863,095 Added 2077.19%
4,049,072 $281 Million
Q4 2022

Feb 06, 2023

SELL
$68.48 - $81.09 $137 Million - $162 Million
-1,995,039 Reduced 91.47%
185,977 $13.4 Million
Q3 2022

Oct 18, 2022

BUY
$0.13 - $76.84 $32,705 - $19.3 Million
251,581 Added 13.04%
2,181,016 $155 Million
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $48.4 Million - $53.3 Million
666,543 Added 52.78%
1,929,435 $149 Million
Q1 2022

Apr 05, 2022

BUY
$61.48 - $73.72 $39.6 Million - $47.5 Million
643,750 Added 103.97%
1,262,892 $92.2 Million
Q4 2021

Feb 03, 2022

BUY
$53.63 - $62.52 $8.69 Million - $10.1 Million
162,036 Added 35.45%
619,142 $38.6 Million
Q3 2021

Oct 15, 2021

BUY
$59.17 - $69.31 $4.01 Million - $4.7 Million
67,741 Added 17.4%
457,106 $27 Million
Q2 2021

Jul 21, 2021

BUY
$61.91 - $67.42 $7.63 Million - $8.31 Million
123,246 Added 46.31%
389,365 $26 Million
Q1 2021

Apr 05, 2021

BUY
$59.34 - $66.74 $385,472 - $433,543
6,496 Added 2.5%
266,119 $16.8 Million
Q4 2020

Jan 20, 2021

BUY
$57.74 - $65.43 $1.09 Million - $1.23 Million
18,874 Added 7.84%
259,623 $16.1 Million
Q3 2020

Oct 19, 2020

BUY
$57.43 - $63.64 $2.44 Million - $2.71 Million
42,560 Added 21.47%
240,749 $14.5 Million
Q2 2020

Jul 29, 2020

BUY
$54.82 - $64.09 $10.9 Million - $12.7 Million
198,189 New
198,189 $11.7 Million
Q1 2020

Apr 23, 2020

SELL
$46.4 - $67.43 $12.6 Million - $18.3 Million
-271,371 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$49.21 - $64.19 $374,340 - $488,293
-7,607 Reduced 2.73%
271,371 $17.4 Million
Q3 2019

Oct 10, 2019

BUY
$42.77 - $50.71 $716,867 - $849,950
16,761 Added 6.39%
278,978 $14.1 Million
Q2 2019

Aug 12, 2019

BUY
$44.62 - $49.34 $5.2 Million - $5.75 Million
116,476 Added 79.92%
262,217 $11.9 Million
Q1 2019

Apr 10, 2019

BUY
$45.12 - $53.8 $6.58 Million - $7.84 Million
145,741 New
145,741 $6.95 Million
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $7.53 Million - $9.76 Million
-154,387 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $998,883 - $1.13 Million
18,099 Added 13.28%
154,387 $9.58 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $3.75 Million - $4.68 Million
74,230 Added 119.61%
136,288 $7.54 Million
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $417,342 - $480,445
6,965 Added 12.64%
62,058 $3.93 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $791,208 - $862,619
13,200 Added 31.51%
55,093 $3.38 Million
Q3 2017

Nov 08, 2017

BUY
$55.23 - $63.74 $2.31 Million - $2.67 Million
41,893
41,893 $2.67 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.